A sad situation. I was a top 20 holder for donkeys years , from...

First 19 Last

Share
Profile

Follow
groundzero

29,310 Posts.

80

20/10/18

21:41

Post #: 36199436
Share

Originally posted by Tadtech: ↑

This is not looking good for shareholders I am afraid.

CAS raised £4m from UK investors back in April via the AIM listing/float at 3p a share, that has gone.
In a matter of months those UK investors had lost nearly 60% of their investment, since then funding conditions on AIM have deteriorated significantly, basically there is no appetite to fund juniors at this time, let alone a company with significant G&A cash burn and woeful historic losses.

The company was then censured by the ASX, they pointed out they would be out of cash by end September, the company responded by saying they had a good history in raising cash in the past. The results were heavily qualified by the auditors also.

The first red flag was during the Q&A session at the Shares event in London a few months ago which can be seen on Hotcopper. The CEO refused to answer questions concerning the cash position which is never a good sign.

I have seen statements like the one CAS made on AIM leading to administration in the majority of cases. Time will tell.

Expand

A sad situation. I was a top 20 holder for donkeys years , from just after they floated. Always believed the story, and there always was one.
Should have sold at $1.50, but believed there was more to come. That was on Borborema hype. Borborema didnt stack up, so came Juruena, which also seemed to have failed, and it was back to Borborema, lol.
a mess.

GZ

CAS Price at posting: 2.0¢ Sentiment: None Disclosure: Not Held
1 Upvote

0 Great analysis

Reply

Top Stories

Is the ASX getting its groove back? Here's 5 IPOs in September to watch

SBW

Shekel Brainweigh investor presentation webinar – the future of retail automation

RMX

Red Mountain Mining: record gold prices, two projects, two greenstone belts

CBA breaks trading record on strong day for Aussie financials

BIT

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo